TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05675046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Carpal Tunnel Release (CTR-US)
Description: The UltraGuideCTR is a commercially available medical device specifically developed to facilitate CTR-US. The device is a single-use, hand-held device that is inserted into the carpal tunnel through a small (typically \< 5 mm) wrist incision using continuous US guidance. The working tip of the UltraGuideCTR consists of two inflatable balloons that border a centrally located, retractable retrograde cutting knife. When inflated with sterile saline, the balloons increase the diameter of the tip from 4 mm to 8 mm. After the tip is positioned within the transverse safe zone of the carpal tunnel, the balloons are inflated to create space in the carpal tunnel, the blade is activated, and the TCL is transected in a retrograde manner. Following TCL transection, the blade is recessed, the balloons deflated, and the device is removed. The TCL is probed to ensure a complete release. The entire procedure is performed using US guidance.
Study: NCT06578936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abdominal massage andwarm application
Description: Abdominal massage and hot application will be applied to the patients at least 30 minutes after the morning and evening meals (08:30 am, 20:30 pm) for 15 minutes each, similar to the literature. The hot application will be applied to the abdominal area with a hot water thermophore for 15 minutes before the abdominal massage. After the hot application, abdominal massage will be started. In the abdominal massage, which will be applied clockwise to stimulate bowel movements, four basic movements will be used: superficial exertion, deep exertion, petrisage and vibration.
Study: NCT05674760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trancutaneous CO2 monitoring (using TCM5 device)
Description: Patients in the Transcutaneous arm will undergo Trancutaneous CO2 monitoring (using TCM5 device)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arterial Blood Gas (ABG) sampling
Description: Arterial Blood Gas (ABG) sampling to monitor CO2 - as per standard practice.
Study: NCT04151225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330811
Description: GSK2330811 will be available as SC injection with a unit dose strength of 150 mg/mL. GSK2330811 will be available in single-use pre-filled syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330811
Description: GSK2330811 will be available as SC injection with a unit dose strength of 150 mg/mL. GSK2330811 will be available in single-use pre-filled syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330811
Description: GSK2330811 will be available as SC injection with a unit dose strength of 150 mg/mL. GSK2330811 will be available in single-use pre-filled syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330811
Description: GSK2330811 will be available as SC injection with a unit dose strength of 150 mg/mL. GSK2330811 will be available in single-use pre-filled syringe.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be available as SC injection of 0.9 percent saline solution. It will be available as single-use pre-filled syringe.
Study: NCT05073575

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No-hyaluronic acid
Description: An access flap will be prepared in order to perform scaling and root planning therapy with the use of metal curettes.~After intervention, a tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 monofilament (polypropylene) non-resorbable suturing materia will be performed
Study: NCT06573450

Intervention type: OTHER
Intervention: questionnaire survey
Description: subjects fill out questionnaires

Intervention type: OTHER
Intervention: questionnaire survey
Description: subjects fill out questionnaires
Study: NCT06574802

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERL + air polishing
Description: Er:YAG laser (ERL) plus sub-gingival air polishing treatment

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ERL
Description: ERL treatment
Study: NCT04023240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: 68Ga-FAPI is quinoline based PET radiopharmaceutical.~68Ga-FAPI is administered intravenously (IV)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) scan
Description: Participants will have a CT scan for attenuation correction and anatomic localization of PET data.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) scan
Description: PET images will be acquired.
Study: NCT06466850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Exosome
Description: intra-articular injection is suggested for two times: day 1and day 90
Study: NCT05340855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wiidookaage'win Facebook Group
Description: A 30-day Facebook group prototype that is moderated by two women who will post various forms of media addressing opioid recovery, mindfulness, stress management, and resiliency.
Study: NCT05627102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Therapeutic Percutaneous Electrolysis an neuromodulation associated with eccentric exercises devices at home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional group
Description: Ultrasound pulsatil therapy (US), transcutaneous electric nerve stimulation (TENS) for 20 minutes and associated with eccentric exercises devices at home.
Study: NCT04979975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PBO- placebo matching to UB-621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-621 low-dose
Description: fully human anti-HSV mAb

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-621 high-dose
Description: fully human anti-HSV mAb
Study: NCT06286150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical robot system
Description: SHURUI Single-port surgical robot system
Study: NCT04845048

Intervention type: BIOLOGICAL
Intervention: Adsorbed COVID-19 (Inactivated) Vaccine
Description: Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac/Butantan Institute

Intervention type: BIOLOGICAL
Intervention: Adsorbed COVID-19 (Inactivated) Vaccine
Description: Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac/Butantan Institute

Intervention type: BIOLOGICAL
Intervention: Adsorbed COVID-19 (Inactivated) Vaccine
Description: Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac/Butantan Institute
Study: NCT05900726

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High Resolution Anorectal Manometry
Description: A test used to measure the strength of the muscles in the anal canal

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: High Resolution Anorectal Manometry
Description: A test used to measure the strength of the muscles in the anal canal

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoanal Ultrasound
Description: An examination of the anal canal (back passage) that allows us to see the muscles involved in passing stool and the tissues that surround these.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Endoanal Ultrasound
Description: An examination of the anal canal (back passage) that allows us to see the muscles involved in passing stool and the tissues that surround these.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowel diary
Description: A daily diary to assess episodes of faecal incontinence

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Bowel diary
Description: A daily diary to assess episodes of faecal incontinence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MYMOP2
Description: Questionnaire to assess individual symptoms, general wellbeing and activity in faecal incontinence

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: MYMOP2
Description: Questionnaire to assess individual symptoms, general wellbeing and activity in faecal incontinence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIQOL
Description: Questionnaire to assess the quality of life with faecal incontinence

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: FIQOL
Description: Questionnaire to assess the quality of life with faecal incontinence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FISI
Description: Questionnaire to assess the severity of faecal incontinence

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: FISI
Description: Questionnaire to assess the severity of faecal incontinence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up call
Description: At 28 days and 3 months post final pelvipower or sham session to assess faecal incontience after study period

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Follow up call
Description: At 28 days and 3 months post final pelvipower or sham session to assess faecal incontience after study period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: St Mark's incontinence score
Description: A score of incontinence

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: St Mark's incontinence score
Description: A score of incontinence
Study: NCT06425549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimekizumab
Description: Study participants receive bimekizumab (BKZ) administered as subcutaneous injection at pre-specified timepoints and dosage regimen during the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimekizumab
Description: Study participants receive bimekizumab (BKZ) administered as subcutaneous injection at pre-specified timepoints and dosage regimen during the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ustekinumab
Description: Study participants receive ustekinumab (USTE) administered as subcutaneous injection at pre-specified timepoints during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Study participants receive placebo at pre-specified timepoints during the study to maintain the blinding.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Study participants receive placebo at pre-specified timepoints during the study to maintain the blinding.
Study: NCT05941130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of corticosteroid (methylprednisolone - Medrol, 16mg Pfizer Laboratories) therapy and non-steroidal anti-inflammatory (Ibuprofen 600mg Mylan) therapy
Description: Facial swelling assessment with a tridimensional method, pain and patient's quality of life will be evaluated after impacted third molar surgery, when NSAID are prescribed either alone (group A) or in combination with a corticosteroid (group B).Patients will be randomized before surgery into two groups regarding postoperative anti-inflammatory prescription.~Half will receive postoperative steroid anti-inflammatory

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory therapy (Ibuprofen 600mg Mylan)
Description: Facial swelling assessment with a tridimensional method, pain and patient's quality of life will be evaluated after impacted third molar surgery, when NSAID are prescribed either alone (group A) or in combination with a corticosteroid (group B).Patients will be randomized before surgery into two groups regarding postoperative anti-inflammatory prescription.~Half will receive postoperative non-steroid anti-inflammatory
Study: NCT06324266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Cyclophosphamide monotherapy for 2 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenalidomide
Description: Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Lenalidomide monotherapy for 2 years.
Study: NCT04417686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arterial embolization
Description: arterial embolization of the geniculated arteries for reduction of pain after installation of total knee prosthesis
Study: NCT06286605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A-oss and autogenous bone
Description: Horizontal ridge augmentation in one stages approach will be performed using a mix of A-Oss and autologenous bone.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A-oss an LCR-A
Description: Horizontal ridge augmentation in one stages approach will be performed using OssMem with A-Oss and LCR-A
Study: NCT06419348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-QULIC-5-P1
Description: Each subject receives a single intravenous injection of 99mTc-QULIC-5-P1.
Study: NCT05575960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Adolescents (IPT-A)
Description: Interpersonal Psychotherapy (IPT) is a psychotherapeutic treatment originally developed for treating depression in adults. It is a brief, structured treatment based on the idea of mobilizing the patient's social network, increasing his/her capacity to accept and seek support from others, and to process interpersonal difficulties, in order to improve depressive symptoms. Interpersonal psychotherapy for adolescents (IPT-A) is a version of IPT designed for young people between the age of 12-18 years with depression (Mufson, 2004), and is in many respects similar to IPT although with some modifications (e.g., a few scheduled meetings with parents during the course of treatment).
Study: NCT06084507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG171/ritonavir
Description: Single oral dose of GST-HG171 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG171/ritonavir
Description: Single oral dose of GST-HG171 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Single oral dose of ritonavir 100 mg at -12 hours prior to GST-HG171/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours and 24 hours after GST-HG171/ritonavir dosing.
Study: NCT05738993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-178
Description: A single intravenous (IV) infusion at a dose of 420 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta
Description: A single intravenous (IV) infusion at a dose of 420 mg
Study: NCT06084507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Single oral dose of ritonavir 100 mg at -12 hours prior to GST-HG171/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours and 24 hours after GST-HG171/ritonavir dosing.
Study: NCT05101525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound to visualize the intra tendinous marker. If this is in place, healing is effective. On the other hand, if it has migrated, there is no scarring.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound to visualize the intra tendinous marker. If this is in place, healing is effective. On the other hand, if it has migrated, there is no scarring.
Study: NCT05711979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AARC
Description: There will be 10 90min weekly sessions. The first half of each session will consist of health education discussing diet, physical activity and screen time. Participants will set goals for themselves and their families. The investigators will check-in on goals and barriers to achieving goals in each session following the initial session. The second half of the sessions will focus on mindfulness based stress reduction including brief meditation, discussion of mindful eating and mindful parenting. This intervention will adapt an already-existing evidence-based obesity prevention program which has been administered to over 100 families (COACH), and it will add mindfulness-based stress reduction, tailored to African American women.
Study: NCT06328764

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CS-101
Description: Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
Study: NCT04618666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic and open surgery intervention
Description: laparoscopic and open surgery to remove an inflammed appendix in chronic appendicitis
Study: NCT05696210

Intervention type: OTHER
Intervention: Transfusion rate of red blood cells
Description: Transfusion rate of red blood cells greater than 7
Study: NCT04945148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 2000 to 3000mg/day daily will be started by 6 weeks after histological diagnosis and 7 days before the start of RT-TMZ and will continue until progression.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation IMRT
Description: 2 Gy x 5 days for 6 weeks to be started 7 days after first administration of Metformin and by 7 weeks after histological diagnosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m² daily from first to last day of radiation (IMRT) and then 150 to 200 mg/m² x 5 days every 28 days cycle for 12 cycles
Study: NCT03915639

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peri-incisional injection
Description: The surgeons are planned to inject the cocktail mixture or ropivacaine to muscles and the subcutaneous tissue beneath the fixation sites and incision site using a 22-gauge needle in a sterile fashion prior to skin incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-incisional injection
Description: The surgeons are planned to inject the cocktail mixture or ropivacaine to muscles and the subcutaneous tissue beneath the fixation sites and incision site using a 22-gauge needle in a sterile fashion prior to skin incision.
Study: NCT05176275

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-RP25
Description: The proliferation and distribution of CD19 CAR-T cells in lymphoma patients were investigated by PET / CT after injection of 68Ga-NOTA-RP25
Study: NCT05831111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195.1
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195.1
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195.1
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195.1
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195.1
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195.1
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195.1
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195.2
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195.2
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195.2
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195.2
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195.2
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195.2
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195.2
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1189
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1189
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT05925933

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention
Description: high protein diet (carbohydrates 45%, protein 29%, and fat 26%) over 8-week periods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: high protein diet (carbohydrates 45%, protein 29%, and fat 26%) over 8-week periods.
Study: NCT05751122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic flex cast with neurodevelopmental treatment
Description: Neurodevelopmental therapy in combination with dynamic flex cast to treat experimental group.~Three times a week, 1 hour session per day.~Dynamic flex casting is casting which manipulate bone alignment and maintains range of motion or sustained stretch. Casting will be changed weekly for 3 months.~Neuro developmental approach is individualized treatment which is attuned to each child's specific problems, aims and goals.~Key elements in NDT are: facilitation (using sensory inputs to improve motor performance), management of compensatory motor behavior, and an overall management strategy (a 24-hour interdisciplinary management approach) NDT involves task specific postures and movements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rigid Ankle foot Orthosis with neurodevelopmental treatment
Description: Rigid ankle foot orthosis will be applied to ankle joint at the start of intervention.~Neurodevelopmental treatment will be applied to both groups with protocol; Three times a week, 1 hour session per day.~Assessment on 1st day,6th week and 12th week
Study: NCT05749848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LY3372689
Description: Administered orally.
Study: NCT06076720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New head-mounted visual aids
Description: New head-mounted visual aids such as Beyes, HOLA, Acesight and OXSIGHT are the latest wearable electronic visual aids
Study: NCT05341258

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EtCO2
Description: EtCO2

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PaCO2
Description: PaCO2
Study: NCT04706702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-EnhanceFitness
Description: Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training